UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2004
ARENA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
DELAWARE |
|
000-31161 |
|
23-2908305 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
|
||||
|
6166 Nancy Ridge Drive, San Diego, California 92121 |
||||
|
(Address of Principal Executive Offices) (Zip Code) |
||||
|
|
||||
|
(858) 453-7200 |
||||
|
(Registrant’s telephone number, including area code) |
||||
|
|
||||
|
N/A |
||||
|
(Former Name or Former Address, if Changed Since Last Report) |
||||
Item 5. Other Events.
Nigel R.A. Beeley, Ph.D. has resigned as Arena Pharmaceuticals, Inc.’s Vice President and head of medicinal chemistry to join Senomyx, Inc., a San Diego based biotechnology company, as Vice President, Discovery.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: June 7, 2004 |
|
Arena Pharmaceuticals, Inc., |
||
|
|
|
a Delaware corporation |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Jack Lief |
|
|
|
|
|
Jack Lief |
|
|
|
|
|
President & Chief Executive Officer |
|
2